Back to results
US 2020/0085997 A1Published application
Synthetic tissue glue
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorHaitao Qian
Life of this patent
Estimating the term…
Abstract
Compositions for use as a tissue glue or sealant are disclosed. The compositions include first and second precursor molecules, wherein the first precursor molecule is a polyoxyethylene-polyoxypropylene block copolymer having at least two nucleophilic groups and the second precursor molecule is a polyoxyethylene-polyoxypropylene block copolymer having at least two electrophilic groups. Biomaterials for use as a tissue glue or sealant, methods of making such biomaterials, devices for applying a biomaterial to a tissue of a patient, methods of sealing a tissue of a patient, and kits also are disclosed.
Claims26
1:
- A composition comprising first and second precursor molecules, wherein:
- i) the first precursor molecule has a formula I or II:
- A-[(C2H4O)m1—(C3H6O)n1-B]y (I)
- or
- A-[(C3H6O)m2—(C2H4O)n2-B]y (II)
- wherein m1, m2, n1, and n2 are independently integers from 1 to 200;
- y is 2 or greater;
- A is a branch point;
- and
- B comprises a nucleophilic functional group;
- ii) the second precursor molecule has a formula III or IV:
- D-[(C2H4O)p1—(C3H6O)q1-E]z (III)
- or
- D-[(C3H6O)p2—(C2H4O)q2-E]z (IV)
- wherein p1, p2, q1, and q2 are independently integers from 1 to 200;
- z is 2 or greater;
- D is a branch point;
- and
- E comprises an electrophilic functional group.
16 more elements
2:
- The composition of claim 1, wherein y is 2 to 8 and z is 2 to 8.
3-5. (canceled)
6:
- The composition of claim 1, wherein the branch point A is selected from the group consisting of carbon, glycerol, pentaerythritol, dipentaerythritol, and ethylene diamine, and the branch point D is selected from the group consisting of carbon, glycerol, pentaerythritol, dipentaerythritol, and ethylene diamine.
(canceled)
8:
- The composition of claim 1, wherein B comprises a thiol group or an amino group.
9:
- The composition of claim 1, wherein E comprises a succinimidyl ester group.
10:
- The composition of claim 1, wherein E is:
- wherein G is absent or —CO(CH2)r—;
- and
- r is an integer from 1 to 5.
1 more element
11-14. (canceled)
15:
- The composition of claim 1, wherein the first precursor molecule has a formula:
- wherein each R1 is
- and
- m1 and n1 are as defined in claim 1.
1 more element
16:
- The composition of claim 1, wherein the first precursor molecule has a formula:
- wherein each R1 is
- and
- m2 and n2 are as defined in claim 1.
1 more element
17:
- The composition of claim 1, wherein the second precursor molecule has a formula:
- wherein each R2 is
- p1 and q1 are as defined in claim 1;
- G is absent or —CO(CH2)r—;
- and
- r is an integer from 1 to 5.
3 more elements
18:
- The composition of claim 1, wherein the second precursor molecule has a formula:
- wherein each R2 is
- p2 and q2 are as defined in claim 1;
- G is absent or —CO(CH2)r—;
- and
- r is an integer from 1 to 5.
3 more elements
19-21. (canceled)
22:
- The composition of claim 1, wherein the composition is substantially free of poly(ethylene oxide) derivatives.
23:
- A dual compartment syringe comprising the first and second precursor molecules of claim 1, where the first precursor molecule is loaded in a first compartment and the second precursor molecule is loaded in a second compartment.
24-47. (canceled)
48:
- The dual compartment syringe of claim 23, further comprising a mixing device.
49:
- A biomaterial formed by reacting the first and second precursor molecules of claim 1.
50:
- A biomaterial comprising a crosslinked polymeric network having a structure:
- wherein m1, m2, n1, n2, p1, p2, q1, and q2 are independently integers from 1 to 200;
- G is absent or —CO(CH2)r—;
- and
- r is an integer from 1 to 5.
2 more elements
51:
- A method of making a biomaterial comprising:
- reacting first and second precursor molecules to form a biomaterial, wherein
- i) the first precursor molecule has a formula I or II:
- A-[(C2H4O)m1—(C3H6O)n1-B]y (I)
- or
- A-[(C3H6O)m2—(C2H4O)n2-B]y (II)
- wherein m1, m2, n1, and n2 are independently integers from 1 to 200;
- y is 2 or greater;
- A is a branch point;
- and
- B comprises a nucleophilic functional group;
- ii) the second precursor molecule has a formula III or IV:
- D-[(C2H4O)p1—(C3H6O)q1-E]z (III)
- or
- D-[(C3H6O)p2—(C2H4O)q2-E]z (IV)
- wherein p1, p2, q1, and q2 are independently integers from 1 to 200;
- z is 2 or greater;
- D is a branch point;
- and
- E comprises an electrophilic functional group;
- and
- the biomaterial is in the form of a crosslinked three dimensional network.
19 more elements
52:
- The method of claim 51, wherein the first and second precursor molecules are reacted under basic conditions.
53:
- The method of claim 51, wherein the first and second precursor molecules are reacted in the presence of a weak base.
54:
- A method of sealing a tissue in a patient, comprising:
- applying to a tissue in a patient the composition of claim 1.
55:
- A kit comprising the first and second precursor molecules of claim 1, wherein the first precursor molecule is in a first container and the second precursor molecule is in a second container.
56-66. (canceled)
Dependencies are inferred from the claim text.